Amgen’s US Amjevita Sales Slow While Other Growth Drivers Deliver
Sales of the Humira biosimilar increased double digits globally year over year, but declined 63% in the US versus Q1 due to inventory stockpiling.
You may also be interested in...
CVS Health’s new subsidiary Cordavis will help manufacturers produce and/or commercialize biosimilars with the aim of reducing overall drug costs while improving access to and affordability of medicines.
As the firm reported Q2 results, AbbVie management offered some insights into how Humira is standing up against US biosimilar adalimumab competition a little better than expected.
As launch dates arrive under settlement agreements with Humira originator AbbVie, multiple firms have introduced adalimumab biosimilars in the US, confirming launch and pricing details – with one biosimilar following in the footsteps of Coherus by announcing an 85% discount to the originator.